AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34281363
Drug: Ticagrelor Monotherapy
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor Monotherapy
Trial: 36535779
Drug: Ticagrelor with
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor with Aspirin
Trial: 34281614
Drug: Community-wide mass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-wide mass drug administration (MDA) for soil-transmitted helminths (STH)
Trial: 34281912
Drug: GSK2636771 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2636771 (200 mg) plus enzalutamide (160 mg)
Trial: 34281912
Drug: GSK2636771 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2636771 (300 mg) plus enzalutamide (160 mg)
Trial: 34281912
Drug: GSK2636771 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2636771 (400 mg) plus enzalutamide (160 mg)
Trial: 34282079
Drug: Outpatient motivational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient motivational enhancement therapy (4 sessions)
Trial: 34282079
Drug: Outpatient motivational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient motivational enhancement therapy followed by community reinforcement approach for seniors (8 sessions)
Trial: 34282496
Drug: Deceased donor
RxNorm normalized name: Dexased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deceased donor liver-derived natural killer (NK) cell infusion
Trial: 34283023
Drug: Tablet intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet intervention containing IPV questions and a film to promote safety behaviors
Trial: 34283629
Drug: Continuous 5-aza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 5-aza treatment
Trial: 34284523
Drug: NF-κB decoy
RxNorm normalized name: NF-kappaB Decoy
DrugBank: NF-kappaB Decoy (DB05559)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NF-κB decoy injection into degenerated IVDs
Trial: 34284523
Drug: NF-κB decoy
RxNorm normalized name: NF-kappaB Decoy
DrugBank: NF-kappaB Decoy (DB05559)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NF-κB decoy injection
Trial: 34284599
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) performed in 175 patients (51.6%); mechanical thrombectomy in 139 patients.
Trial: 34284599
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) group.
Trial: 34285010
Drug: Smartphone application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone application for data collection including personal profile, monthly event tracker, and patient-reported outcomes instruments.
Trial: 34285010
Drug: Myasthenia Gravis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myasthenia Gravis Activities of Daily Living
Trial: 34285598
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg once daily (days 1-5) + Trazpiroben 25 mg post itraconazole on day 4
Trial: 34286103
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose rifampicin and adjunctive linezolid, with or without aspirin
Trial: 34286354
Drug: Best possible
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best possible medication history (BPMH) by hospital pharmacist at inclusion and therapeutic drug monitoring
Trial: 34286454
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 100 U/mL (Gla-100) starting dose of 0.3 U/kg
Trial: 34286454
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 100 U/mL (Gla-100) starting dose of 0.2 U/kg
Trial: 34286459
Drug: VP-102 topical
RxNorm normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VP-102 topical application once every 14 days (Cohort 1)
Trial: 34286459
Drug: VP-102 topical
RxNorm normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VP-102 topical application once every 21 days in conjunction with paring (Cohort 2)
Trial: 34286886
Drug: Pharmacy administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacy administration and dispensing of methadone for MMT (5-160 mg/day for 3 months)
Trial: 34286886
Drug: Pharmacy administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacy administration and dispensing of methadone for MMT
Trial: 34287023
Drug: Sertraline; specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline; specific dosage and duration not available
Trial: 34287217
Drug: Community-based screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based screening using an oral fluid-based rapid test (OFT)
Trial: 34287262
Drug: Changing the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changing the time of day for taking endocrine therapy (tamoxifen and/or aromatase inhibitors)
Trial: 34287942
Drug: Lanadelumab 300
RxNorm normalized name: lanadelumab 300 mg in 2 mL SUBCUTANEOUS SOLUTION [TAKHZYRO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanadelumab 300 mg q2wks
Trial: 34288026
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of post-transplant cyclophosphamide
Trial: 34288271
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (levodopa)
Trial: 34288547
Drug: Lorlatinib oral
RxNorm normalized name: lorlatinib Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib oral solution
Trial: 34289017
Drug: Ibrutinib (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (420 mg/d) and ulocuplumab (cycles 1 to 6, 4 weeks each)
Trial: 34289656
Drug: Rituximab 375
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m2 (single dose) and oral prednisone (for at least 5 days) prior to chemoimmunotherapy
Trial: 34289656
Drug: Rituximab/prednisone prephase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab/prednisone prephase treatment
Trial: 34289656
Drug: Prephase treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prephase treatment
Trial: 34291703
Drug: Carbon dioxide
RxNorm normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbon dioxide (CO2) laser treatment, 3 sessions over 20 weeks
Trial: 34291703
Drug: Histological analysis
RxNorm normalized name: Entamoeba histolytica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histological analysis after CO2 laser treatment
Trial: 34291703
Drug: Immunohistochemical analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunohistochemical analysis after CO2 laser treatment
Trial: 34291813
Drug: Systemic corticosteroids
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant
Trial: 34292174
Drug: Selective RET-inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective RET-inhibitors (selpercatinib and pralsetinib)
Trial: 34292174
Drug: Investigation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigation of immune-based therapy
Trial: 34292214
Drug: First dose
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First dose of CoronaVac vaccine
Trial: 34292516
Drug: Propofol sedation
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol sedation (0.03 mg/kg)
Trial: 34292537
Drug: Ba-Duan-Jin (BDJ)
RxNorm normalized name: Yu Jin
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ba-Duan-Jin (BDJ) exercise and placebo capsule
Trial: 34292537
Drug: Pregabalin capsule
RxNorm normalized name: Pregabalin Capsules
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin capsule and wellness education with guided muscle-relaxation exercises
Trial: 34293119
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma with high neutralizing antibody titers
Trial: 34293201
Drug: Intensity-modulated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensity-modulated radiation therapy with concurrent doxorubicin (CC-IMRT)
Trial: 34293201
Drug: Intensity-modulated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensity-modulated radiation therapy alone (IMRT)
Trial: 34293527
Drug: Single-dose L-theanine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose L-theanine
Trial: 34295813
Drug: Postoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiotherapy with intensity-modulated radiation therapy (IMRT) at a total dose of 40 Gy in 20 fractions.
Trial: 34296417
Drug: Moxidectin 8
RxNorm normalized name: Advantage Multi for Cats (imidacloprid 80 MG / moxidectin 8 MG) per 0.8 ML Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxidectin 8 mg fixed-dose
Trial: 34296417
Drug: Moxidectin weight-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxidectin weight-based dosing
Trial: 34296674
Drug: Non-pharmaceutical interventions
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pharmaceutical interventions (NPI)
Trial: 34297046
Drug: Azacitidine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azacitidine (75 mg/m2) administered IV once daily on days 1 to 7 of a 28-day cycle
Trial: 34297259
Drug: Online training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online training system with a 32-exercise training course providing online instruction (about 15 min/week) in 13 core family therapy techniques.
Trial: 34297797
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of IGF-1 to old mice
Trial: 34297797
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of anti-TNF-α antibodies to human patients
Trial: 34298376
Drug: Recommended treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended treatments (R-T) for first-line (1L) patients
Trial: 34298376
Drug: Non-recommended treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-recommended treatments (NR-T) for first-line (1L) patients
Trial: 34298376
Drug: Recommended treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended treatments (R-T) for pre-treated (2L+) patients
Trial: 34298376
Drug: Non-recommended treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-recommended treatments (NR-T) for pre-treated (2L+) patients
Trial: 34301808
Drug: Pacmilimab 10
RxNorm normalized name: Pacmilimab
DrugBank: Pacmilimab (DB18873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacmilimab 10 mg/kg + Ipilimumab 3 mg/kg administered every 3 weeks
Trial: 34301809
Drug: Pacmilimab at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacmilimab at a recommended phase 2 dose (RP2D) of 10 mg/kg administered intravenously every 14 days
Trial: 34301809
Drug: Pacmilimab at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacmilimab at RP2D of 10 mg/kg
Trial: 34302290
Drug: Ceftazidime 40
RxNorm normalized name: CEFTAZIDIME 40ML/ML INJ,50ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 40 mg/kg IV q6h (max 8 g/day)
Trial: 34302533
Drug: Imatinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib monotherapy
Trial: 34302589
Drug: Eribulin 1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin 1.4 mg/m² in combination with trastuzumab and pertuzumab (HP)
Trial: 34302589
Drug: Eribulin 1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin 1.4 mg/m²
Trial: 34302760
Drug: Bictegravir, emtricitabine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bictegravir, emtricitabine, and tenofovir alafenamide (single-tablet regimen)
Trial: 34302788
Drug: Polyomavirus-specific T
RxNorm normalized name: Allogeneic JC polyomavirus-specific T-cell therapy
DrugBank: CE-VST01-JC (DB17190)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyomavirus-specific T cells infusion
Trial: 34304968
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg/day for up to 3 years, in addition to ongoing corticosteroid treatment.
Trial: 34304968
Drug: Tamoxifen treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen treatment.
Trial: 34305948
Drug: GC5107 (10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC5107 (10% intravenous immunoglobulin) administered at doses ranging from 319 to 881 mg/kg body weight every 21 or 28 days
Trial: 34305948
Drug: GC5107 (10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC5107 (10% intravenous immunoglobulin)
Trial: 34306227
Drug: Tobacco cessation
RxNorm normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobacco cessation treatment (prescription for nicotine replacement therapy and referral to the quitline)
Trial: 34307126
Drug: Neoadjuvant pegylated
RxNorm normalized name: antihemophilic factor (recombinant) pegylated Injection [Adynovate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant pegylated liposomal doxorubicin (PLD) 35 mg/m²
Trial: 34307246
Drug: Initial steroid
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial steroid treatment, dosage and duration not specified
Trial: 34307504
Drug: Plasma Purification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma Purification Treatment
Trial: 34308309
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg DHA per day
Trial: 34308309
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg DHA per day
Trial: 34309636
Drug: Nilotinib 230
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib 230 mg/m2 twice daily
Trial: 34309846
Drug: Cam-FOLFOX4 (Camrelizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cam-FOLFOX4 (Camrelizumab 3 mg/kg iv drip injection every 2 weeks plus FOLFOX4)
Trial: 34309846
Drug: Cam-GEMOX (Camrelizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cam-GEMOX (Camrelizumab 3 mg/kg iv drip injection every 2 weeks plus GEMOX)
Trial: 34310027
Drug: Risk-prediction score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk-prediction score based on chemotherapy intensity, time since diagnosis, and type of malignancy.
Trial: 34310027
Drug: Intermittent antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent antibiotic prophylaxis (4.3 months to prevent one FN with bacteremia, 5.2 months to prevent one FN with SRE).
Trial: 34310436
Drug: Biochemical resolution
RxNorm normalized name: Revolution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biochemical resolution (total bilirubin [TB] ≤1 mg/dL and ALT <35 U/L)
Trial: 34310436
Drug: Partial resolution
RxNorm normalized name: Revolution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial resolution (TB >1 mg/dL and/or ALT >35 U/L)
Trial: 34310436
Drug: GGT <100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GGT <100 U/L at baseline
Trial: 34310835
Drug: Chemotherapy (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (1 to 5 courses)
Trial: 34312462
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of mb-IL21 ex vivo expanded donor-derived NK cells
Trial: 34312483
Drug: Anti-GITR neutralizing
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-GITR neutralizing antibodies
Trial: 34312483
Drug: Accelerated radiation
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated radiation therapy
Trial: 34312556
Drug: CAR19 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAR19 treatment
Trial: 34465306
Drug: Weekly voluntary
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly voluntary screening for SARS-CoV-2 with a high sensitivity molecular-based saliva test
Trial: 34314483
Drug: Danicopan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danicopan (100 to 200 mg thrice daily)
Trial: 34315419
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine (LB) 266 mg
Trial: 34315767
Drug: Dilpacimab (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilpacimab (3.75 mg/kg)
Trial: 34315767
Drug: Dilpacimab (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilpacimab (various doses 1.25-7.5 mg/kg)
Trial: 34315767
Drug: Dilpacimab (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilpacimab (various doses)
Trial: 34315793
Drug: Ripasudil 0.4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ripasudil 0.4% eye drops administered once daily for 1 week, then two times per day for 2 weeks in phase I, and two times per day for 12 weeks in phase II.
Trial: 34315821
Drug: Avelumab added
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab added to standard treatment
Trial: 34315890
Drug: Treatment-related amenorrhea
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-related amenorrhea (TRA)
Trial: 34319245
Drug: Remote Patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote Patient Monitoring System (RPMS) for 3 months; includes a tablet, weight scale, and pedometer providing daily educational content, weekly weigh-ins.
Trial: 34319435
Drug: Paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel plus cisplatin and 5-fluorouracil (TPF) induction chemotherapy
Trial: 34319435
Drug: Surgery after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery after TPF chemotherapy
Trial: 34319435
Drug: Radical concurrent
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical concurrent chemoradiotherapy after TPF chemotherapy
Trial: 34319435
Drug: TPF chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPF chemotherapy alone
Trial: 34319564
Drug: SNAC 3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNAC 3.6 g
Trial: 34320785
Drug: Temsirolimus (TEM)
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus (TEM) 25 mg weekly and Lenalidomide (LEN) 20 mg on days 1-21 every 28 days
Trial: 34320949
Drug: Continuing secondary
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing secondary antibiotic prophylaxis
Trial: 34320980
Drug: Systemic glucocorticoid
RxNorm normalized name: Glucocorticoids, Systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic glucocorticoid treatment (specific dosage and duration not mentioned)
Trial: 34321280
Drug: Pexidartinib (600-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pexidartinib (600-1000 mg daily) and Sirolimus (2-6 mg daily)
Trial: 34321280
Drug: Pexidartinib and
RxNorm normalized name: pexidartinib
DrugBank: Pexidartinib (DB12978)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pexidartinib and Sirolimus combination therapy
Trial: 34321583
Drug: Regorafenib administered
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib administered for > 3 weeks
Trial: 34321921
Drug: MPS-HA2% (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPS-HA2% (single injection)
Trial: 34322164
Drug: Suprachoroidal injection
RxNorm normalized name: NIACINAMIDE 5 g in 100 g SUPRACHOROIDAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprachoroidal injection of triamcinolone acetonide suspension (CLS-TA)
Trial: 34322164
Drug: Systemic or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic or locally administered corticosteroids